Monoclonal antibodies have emerged as the most successful class of biological therapeutics, providing excellent efficacy and safety profiles. Scores have been approved for use in human and hundreds more are currently in clinical trials for a broad range of indications. Monoclonal antibodies give scientists the ability to marshal the immune system against target molecules, cells or pathogens.
Transgenic mice have become a preferred means to generate fully-human monoclonal therapeutics. First-generation versions of such mice were, however, limited because they expressed only a fraction of the normal human antibody diversity. TRIANNI used advanced DNA synthesis and other techniques to overcome these limitations and create a powerful, easily accessible next-generation drug discovery resource.
The Trianni Mouse™
Genetically engineered mice now act as robust engines for the generation of diverse repertoires of affinity-matured, fully-human variable regions with intrinsic drug-like properties necessary for successful development including high potency, specificity, manufacturability, solubility and low risk of immunogenicity. Few existing or contemplated human transgenic mouse platforms express a full human antibody repertoire. The Trianni Mouse is the only one to do so in a single organism.